Upcoming FDA Guidance Will Offer New Thinking On Drug-Eluting Stents
This article was originally published in The Gray Sheet
Executive Summary
FDA plans to issue a guidance document on drug-eluting stents in the next several months to communicate new premarket and postmarket recommendations for the heavily scrutinized products
You may also be interested in...
A Conversation With FDA Interventional Cardiology Reviewer Andrew Farb
When FDA needed experts to guide its response to the emerging drug-eluting stent thrombosis issue in 2006, it was lucky to find it already had a cardiovascular pathologist experienced with implantable devices on its review staff
A Conversation With FDA Interventional Cardiology Reviewer Andrew Farb
When FDA needed experts to guide its response to the emerging drug-eluting stent thrombosis issue in 2006, it was lucky to find it already had a cardiovascular pathologist experienced with implantable devices on its review staff
FDA Previews New Drug-Eluting-Stent Guidance At CRT Meeting In D.C.
FDA's upcoming drug-eluting-stent guidance will emphasize long-term safety and shift the focus of trials from surrogate to clinical endpoints